Benzinga · Oct 12, 2026
BTIG Maintains Buy on AVITA Medical, Raises Price Target to $15
BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $11 to $15.
RC
NASDAQ · RCEL
AVITA Medical, Inc.
Healthcare · Medical - Devices
$15.41
Down-$0.24 (-1.53%)
Updated Nov 3, 2026, 8:07 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 94.53M
- P/E ratio
- -1.8
- Dividend yield
- 0.00%
- 52-week range
- $3.22 – $16.90
- Volume
- 492.24K
- Avg. volume
- 574.48K
Price performance · RCEL
RCEL price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
RCEL closed at $15.41 after 21 trading sessions, up 16.30% for the selected period.
- Last close
- $15.41
- Period change
- +16.30%
- Period low
- $12.99
- Period high
- $16.71
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $15.65 | $15.71 | $14.67 | $15.41 | 492.24K |
| Oct 30, 2026 | $16.54 | $16.60 | $15.2426 | $15.65 | 597.05K |
| Oct 29, 2026 | $16.71 | $16.90 | $16.40 | $16.71 | 312.93K |
| Oct 28, 2026 | $15.82 | $16.68 | $15.68 | $16.50 | 459.08K |
| Oct 27, 2026 | $15.25 | $16.13 | $15.11 | $16.08 | 545.27K |
| Oct 26, 2026 | $15.50 | $15.535 | $14.83 | $15.18 | 323.85K |
| Oct 23, 2026 | $15.37 | $15.615 | $14.28 | $15.51 | 401.52K |
| Oct 22, 2026 | $15.16 | $15.68 | $15.00 | $15.42 | 652.6K |
| Oct 21, 2026 | $13.95 | $15.6405 | $13.95 | $15.29 | 844.79K |
| Oct 20, 2026 | $13.29 | $14.08 | $13.29 | $13.80 | 422.05K |
| Oct 19, 2026 | $13.01 | $13.44 | $12.70 | $13.14 | 267.14K |
| Oct 16, 2026 | $13.37 | $13.49 | $12.95 | $13.04 | 318.5K |
| Oct 15, 2026 | $13.02 | $13.58 | $12.8937 | $13.41 | 388.79K |
| Oct 14, 2026 | $13.16 | $13.2834 | $12.80 | $13.10 | 525.64K |
| Oct 13, 2026 | $13.41 | $13.70 | $13.15 | $13.36 | 297.58K |
| Oct 12, 2026 | $13.32 | $13.73 | $12.91 | $13.37 | 319.81K |
| Oct 9, 2026 | $13.49 | $13.71 | $13.00 | $13.21 | 280.48K |
| Oct 8, 2026 | $12.87 | $13.40 | $12.53 | $13.33 | 347.91K |
| Oct 7, 2026 | $12.82 | $13.31 | $12.5853 | $13.05 | 263.05K |
| Oct 6, 2026 | $13.38 | $13.495 | $12.39 | $12.99 | 409.88K |
| Oct 5, 2026 | $12.64 | $13.48 | $12.5341 | $13.25 | 420.76K |
Latest RCEL news
The latest Smart Investors Daily articles mentioning RCEL.
Stock researchCompany · Overview
Company
Market Activity
Research & News
RCEL research
Overview
Company profile and research snapshot.
Company profile
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $4.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 12, 2026 | BTIG | Buy | — |
| Aug 28, 2026 | Lake Street | Buy | — |
| Aug 19, 2026 | BTIG | Buy | — |
| Aug 19, 2026 | TD Cowen | Buy | — |
| Aug 7, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 12, 2026
AVITA Medical Q2 2026 Earnings Call Transcript
On Thursday, AVITA Medical (NASDAQ:RCEL) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call transcripts
SeekingAlpha · Oct 11, 2026
Leading Indicators For The October Breakout Cycle
Explore Q4 S&P 500 seasonality and the October breakout cycle after midterms.
Yahoo · Aug 25, 2026
AVITA Medical (RCEL) Stock Fair Value Rises After PermeaDerm Data And Analyst Target Increases
AVITA Medical is back in focus after fair value estimates in recent models shifted from US$9.00 to US$11.06, marking a sizeable uplift in the central price target. Analysts link these updated targets to new PermeaDerm-I data, RECELL usage trends, reimbursement developments and changes to the Stedical agreements, as they reassess how AVITA Medical might scale its burn care portfolio. As you read on, you will see how these moving targets fit into the broader narrative and what to watch to stay...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
